MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI\u2122 (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson\u2019s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa\/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or other symptoms. These disruptive episodes can occur any time throughout the day and get worse as the disease progresses. KYNMOBI was previously approved by the U.S. Food and Drug Administration (FDA) on May 21, 2020. <\/p>\n
\u00ab\u00a0As the disease progresses patients with Parkinson\u2019s are faced with challenging and disruptive OFF episodes that come with impaired mobility,\u00a0\u00bb said Karen Lee, PhD, CEO of Parkinson Canada. \u201cToday\u2019s Health Canada approval is an important step forward for people living with Parkinson\u2019s disease, as they now have more options that can help manage the effects of OFF episodes as they occur.\u00a0\u00bb <\/p>\n
to read the entire press release, visit https:\/\/news.sunovion.com\/press-releases\/ <\/p>\n","protected":false},"excerpt":{"rendered":"